https://visualize.jove.com/42673600-in-hfmref-or-hfref-digitalis-glycosides-reduce-a-composite-of-cv-death-or-worsening-hf-event-vs-placebo-at-a-median-36-to-37-mo
In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs....
Aug 31, 2026 - Explore new formulas in General Internal Medicine, Family Practice, and Cardiology for improved clinical impact and patient outcomes.
digitalis glycosideshfmrefhfrefreducecomposite
https://www.oppc.com/tag/hfref/
HFrEF Archives - OnePoint Patient Care
patient carehfrefarchives
https://cvgk.nl/news/voordelen-van-uitgebreide-ziektemodificerende-farmacologische-therapie-bij-patienten-met-hfref/2465529/
Voordelen van uitgebreide ziektemodificerende farmacologische therapie bij patiënten met HFrEF -...
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a…
voordelenvanuitgebreidefarmacologischetherapie
https://www.cdleycom.com/tag/hfref/
HFrEF Archives - CD Leycom
hfrefarchives
https://naturaldatabase.therapeuticresearch.com/Content/Articles/PL/2024/Sep/Help-Troubleshoot-Med-Regimens-for-HFrEF
Help Troubleshoot Med Regimens for HFrEF
helptroubleshootmedregimenshfref
https://sofinnovapartners.com/news/nanophoria-bioscience-secures-eur83-5-million-series-a
NanoPhoria raises €83.5M Series A for HFrEF therapy — Sofinnova Partners
Oct 6, 2025 - NanoPhoria Bioscience raises €83.5M Series A led by XGEN Venture and Sofinnova to advance NP-MP1, a first-in-class HFrEF cardiac peptide.
series araiseshfreftherapysofinnova